DUBLIN--(BUSINESS WIRE)--Jun 14, 2018--The "Viral Vectors and Plasmid DNA Manufacturing Market (2nd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The Viral Vectors and Plasmid DNA Manufacturing Market (2nd Edition), 2018-2030 report offers a comprehensive study of the current scenario of manufacturing of viral and non-viral vectors that are primarily used for the development of gene therapies and T-cell therapies. The study features an in-depth analysis, highlighting the capabilities of a diverse set of players, covering both contract manufacturers and companies with in-house capabilities.

Genetically modified therapies have emerged as a promising treatment option for various diseases (primarily ones that currently have no cure), including cancers, inherited disorders and certain viral infections. These therapies have demonstrated the potential to treat chronic indications, such as Alzheimer's disease, Parkinson's disease and rheumatoid arthritis, as well. Gene therapies, and other therapies that require genetic modification, involve the introduction of therapeutic DNA / gene of interest into a patient's body / cells. This process is accomplished by the use of vectors. Over the last few decades, various viral and non-viral vectors have been developed, optimized and standardized for this purpose.

Currently, the most popular viral vectors, on the basis of their use in active clinical trials, are those based on AAV, adenovirus, lentivirus and retrovirus. On the other hand, among non-viral gene delivery tools, plasmid DNA has emerged as the preferred option. Plasmid DNA is also used in the development and production of viral vectors and DNA vaccines. Recent advances have led to the emergence of several other innovative viral / non-viral gene delivery approaches that are being utilized for development of various therapies that require gene modification.

Overall, eleven genetically modified therapies have been approved so far; these are (in the order of approval, most recent first) LUXTURNA, YESCARTA, Kymriah, INVOSSA, Zalmoxis, Strimvelis, Imlygic, Neovasculagen, Rexin-G, Oncorine and Gendicine. Amongst these, YESCARTA and Kymriah are T-cell based gene therapies that were recently approved by the FDA, in October 2017 and August 2017, respectively.

In addition, over 430 gene therapy candidates are presently in different stages of clinical development, for which over 500 clinical studies are currently underway in various regions across the globe. The growing number of gene therapy candidates, coupled with their rapid progression through various phases of clinical development, is expected to continue to create an increasing demand for vectors.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Viral Vector Manufacturers: Competitive Landscape

5. Plasmid DNA Manufacturers: Competitive Landscape

6. Viral Vectors And Plasmid DNA Manufacturing In North America

7. Viral Vectors And Plasmid DNA Manufacturing In Europe

8. Viral Vectors And Plasmid DNA Manufacturing In Asia-Pacific

9. Emerging Vectors

10. Recent Collaborations And Partnerships

11. Key Insights

12. Viral Vectors And Plasmid DNA: Cost Price Analysis

13. Capacity Analysis

14. Market Sizing And Opportunity Analysis

15. Drivers And Challenges

16. Survey Analysis

17. Conclusion

18. Executive Insights

For more information about this report visit https://www.researchandmarkets.com/research/w25353/global_viral?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180614005502/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/14/2018 07:15 AM/DISC: 06/14/2018 07:15 AM

http://www.businesswire.com/news/home/20180614005502/en